Abdera Therapeutics

We are thrilled to announce that we have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ABD-147 for the treatment of patients with extensive stage small cell #lungcancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy. ABD-147 is our lead next-generation precision #radiopharmaceutical biologic therapy designed to target solid tumors expressing DLL3, a protein found on the surface of neuroendocrine tumors including SCLC, but rarely expressed on the surface of normal cells or tissues. Read more: https://lnkd.in/eh-57eFh

At Abdera, we are proud to foster an environment that allows everyone to bring their most authentic selves to work every day as we propel our mission to attack #cancer. This #PrideMonth, associate scientist Etienne Melese, Ph.D., shares what this month means to him, how identity matters, and how we all need a space to feel accepted. 🏳️🌈

Today, we are observing #Juneteenth in our U.S. offices. We are taking the day to reflect on the meaning of freedom for all Americans. As we strive to develop tomorrow’s most innovative cancer therapies, we must also remember the adversity that many faced in the past.

Abdera President and Chief Executive Officer Lori Lyons-Williams will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit to speak on how our platform utilizes this emerging therapy. Learn more about our precision #radiotherapeutics platform here: https://lnkd.in/gR5GcxDa

Happy #FathersDay to the incredible fathers and father figures who masterfully balance work and family. May your day be filled with love, relaxation, and cherished moments with your loved ones. Enjoy the celebration and take the time to recharge. #LifeatAbdera

Do you want to be at the forefront of life-changing cancer treatments? At Abdera, we are relentless in our focus to offer new hope to families facing devastating diagnoses. We are offering opportunities to join a collaborative and growing environment to make a difference. We are hiring for the following positions in our Vancouver, British Columbia and San Francisco, California offices, respectively: 🧬 Principal Scientist, Biologics (Vancouver) 🧬 Associate Director, Clinical Quality Assurance (San Francisco) Explore all open positions and apply to join our team here: https://lnkd.in/g_PctqS9 #jobalert #LifeatAbdera

Abdera cofounder and chief operating officer, Lana Janes, Ph.D., will be leading a panel at the 2024 Canadian Radiotheranostics Leaders' Summit, presented by the Canadian Nuclear Isotope Council, tomorrow in Toronto. Dr. Janes will be leading a panel on radiotheranostics, discussing the advancement of innovative treatments from clinical settings to commercial application. For more about this event, please visit https://lnkd.in/g487HwAp

We are excited to attend Jefferies Global Healthcare Conference 2024 among peers and other industry leaders. Learn more about our targeted #radiotherapeutics platform ahead of #JefferiesHealthcare here: https://lnkd.in/gR5GcxDa

#NationalCancerSurvivorsDay, a time to celebrate the inspiring individuals who have triumphed over cancer and to raise awareness about the ongoing challenges survivors face. At Abdera, we are dedicated to advancing our pipeline of radiotherapeutics, providing cutting-edge treatments to create more happy beginnings for those battling cancer. Learn more about #NCSD2024 from the National Cancer Survivors Day Foundation, Inc.: https://lnkd.in/eSRDsQ3

We are excited to announce the clearance of our investigational new drug application (IND) by the U.S. FDA for ABD-147 for the treatment of small cell #lungcancer. ABD-147 is a next-generation precision #radiopharmaceutical therapy designed to deliver Actinium-225, a highly potent radioisotope, to solid tumors expressing DLL3. Learn more about our novel treatment and innovative ROVEr™ platform here: https://lnkd.in/esxvb9dQ